Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$18.95 USD
+0.36 (1.94%)
Updated Jul 22, 2024 03:59 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CHGCY 18.95 +0.36(1.94%)
Will CHGCY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CHGCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CHGCY
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why
CHGCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for CHGCY
Roche receives FDA clearance on its digital pathology solution for diagnostic use
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
Chugai Pharmaceutical Co., Ltd. 2024 Q1 - Results - Earnings Call Presentation
Chugai Pharmaceutical Co., Ltd. (CHGCF) Q1 2024 Earnings Call Transcript